Loading…
Loading…
Not every CLL needs treatment on day one — but every CLL needs accurate risk assessment
Chronic lymphocytic leukemia (CLL) is a clonal proliferation of mature B lymphocytes. Many patients are asymptomatic at diagnosis and are monitored rather than treated. Treatment is indicated for progressive marrow failure, bulky or symptomatic disease, or rapid progression. Modern targeted agents have changed the treatment landscape, and TP53 status and IGHV mutation status inform choice.
Haematology & Haemato-Oncology
Authored and reviewed by Dr. Sachita Baniya (MBBS, FCPS (Clinical Haematology), NMC 20158). Evidence-based, no fabricated outcomes.
Chronic lymphocytic leukemia (CLL) is a clonal proliferation of mature B lymphocytes. Many patients are asymptomatic at diagnosis and are monitored rather than treated. Treatment is indicated for progressive marrow failure, bulky or symptomatic disease, or rapid progression. Modern targeted agents have changed the treatment landscape, and TP53 status and IGHV mutation status inform choice.
Reviewed by Dr. Sachita Baniya, MBBS, FCPS — Consultant Haemato-Oncologist & Clinical Hematologist (NMC 20158). For evaluation, contact the respective hospital or cancer centre — Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital Kathmandu, or Advanced Care Hospital.
Diagnosis requires a persistent clonal B-cell lymphocytosis, confirmed by flow cytometry. FISH, TP53 sequencing and IGHV mutation status provide prognostic and predictive information. Staging, blood counts, spleen and node assessment, and a screen for autoimmune cytopenias complete the baseline. A bone marrow examination is not routinely needed if the blood and flow findings are diagnostic.
Asymptomatic early-stage disease is observed. Treatment is considered for progressive cytopenias, symptomatic or bulky lymphadenopathy or splenomegaly, systemic symptoms, or rapid lymphocyte doubling. Targeted agents — BTK inhibitors, BCL2 inhibitors and combinations — are selected according to TP53 status, comorbidity, drug interactions and patient preference. Supportive care includes infection prevention and vaccination review.
Guidelines referenced:
iwCLL guidelines for diagnosis, indications for treatment and response assessmentNCCN Guidelines — CLL/SLLWHO Classification of Haematopoietic and Lymphoid TumoursContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.